Previous Close | 157.40 |
Open | 156.45 |
Bid | 157.05 x 0 |
Ask | 157.25 x 0 |
Day's Range | 155.50 - 158.35 |
52 Week Range | 125.55 - 222.00 |
Volume | |
Avg. Volume | 557,954 |
Market Cap | 12.257B |
Beta (5Y Monthly) | 1.34 |
PE Ratio (TTM) | 8.19 |
EPS (TTM) | 19.20 |
Earnings Date | May 08, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 277.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for BAVA.CO
COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS® (MVA-BN) for active immunization against disease caused by smallpox, mpox and vaccinia viruses in adults 18 years of age and older. The approval represents the first national marketing authorization issued to Bavarian Nordic since 2019 and was facilitated by the Swiss authorities in response to the 2022 global mpox outbreak. Durin
COPENHAGEN, Denmark, March 12, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523. The transactions concern the vesting of restricted stock units (RSUs) including matc
COPENHAGEN, Denmark, March 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2023. The consolidated, audited results were in line with the preliminary results, announced on February 21, 2024, and exceeded prior guidance. The full report is attached as a PDF file and can be found on the Company's website, www.bavarian-nordic.com. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “Delivering our best-ever financial results in 2023, we are now